NCT00437502View on ClinicalTrials.gov

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions
BIOLOGICAL

tumor peptide vaccine

Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.

BIOLOGICAL

tumor peptide vaccine

Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Collaborators (1)

Immunotope
All Listed Sponsors
collaborator

Immunotope

INDUSTRY

lead

Michael Morse, MD

OTHER

NCT00437502 - A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer | Biotech Hunter | Biotech Hunter